MedPath

ONO-4578-06:Phase I study of ONO-4578 and letrozole plus CDK4 /6 inhibitors in breast cancer

Phase 1
Conditions
breast cancer
Registration Number
JPRN-jRCT2031210364
Lead Sponsor
Osawa Masahiro
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
40
Inclusion Criteria

1. Patients with postmenopausal metastatic or recurrent breast cancer
2. Patients with ECOG Performance Status 0 to 1
3. ER-positive, PgR-positive and HER2-negative patients

Exclusion Criteria

1.Patients are unable to swallow oral medications
2.Patients with severe complication

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety and tolerability
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath